购物车
  • TargetMol
    您的购物车当前为空

Golvatinib

Synonyms: 戈伐替尼, E-7050
货号 T6517Cas号 928037-13-2 一键复制产品信息纯度: 99.50%
Rating icon 很棒

Golvatinib (E-7050) 是一种 c-Met (IC50:14 nM) 和 VEGFR2 (IC50:16 nM) 的双重抑制剂。

Golvatinib

一键复制产品信息
Rating icon 很棒

纯度: 99.50%

货号 T6517Cas号 928037-13-2

别名 戈伐替尼, E-7050

Golvatinib (E-7050) 是一种 c-Met (IC50:14 nM) 和 VEGFR2 (IC50:16 nM) 的双重抑制剂。

Golvatinib
其他形式的 “Golvatinib”:
规格价格库存数量
1 mg
¥ 248
现货
2 mg
¥ 355
现货
5 mg
¥ 578
现货
10 mg
¥ 913
现货
25 mg
¥ 1,750
现货
50 mg
¥ 3,160
现货
100 mg
¥ 4,630
现货
库存状态实时更新,以官网显示为准,现货产品可直接加购物车下单
大包装 & 定制
加入购物车

TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。

实验操作小课堂
常见问题解答
查看更多

选择批次:
纯度: ≥95%
颜色: 白色
资源下载: COA LCMS HNMR产品操作手册

产品介绍


生物活性
产品描述
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.
靶点活性
c-Met:14 nM, VEGFR2:16 nM
体外活性

体外研究表明,Golvatinib 强效抑制 c-Met 和 VEGFR-2 的磷酸化作用。Golvatinib 同时也强效抑制了经 HGF 或 VEGF 刺激的 c-met 扩增肿瘤细胞和内皮细胞的生长。[1] Golvatinib 通过在体外阻断 Met/Gab1/PI3K/Akt 途径,克服了由外源和/或内源 HGF 引发的,对所有可逆的、不可逆的及突变选择性的 EGFR-TKIs 耐药性 EGFR 突变型肺癌细胞系的抵抗。Golvatinib 还能阻止因持续暴露于 HGF 而诱导的 gefitinib 抵抗性 HCC827 细胞的出现。[2]

体内活性

在体内研究中,使用Golvatinib展示了对肿瘤中c-Met与VEGFR-2磷酸化的抑制,以及异种移植模型中肿瘤生长和肿瘤血管生成的显著抑制。对含有c-met扩增的某些肿瘤细胞系用高剂量Golvatinib(50-200 mg/kg)处理,可诱导肿瘤退缩和消失。在腹膜播散模型中,Golvatinib对腹膜肿瘤显示出抗肿瘤效果,并显著延长了受治疗小鼠的寿命。[1] 另一项异种移植模型研究中,由HGF转染的Ma-1(Ma-1/HGF)细胞产生的肿瘤比载体对照肿瘤更易于血管生成,并表现出对ZD1839的抗性。Golvatinib单独应用可抑制血管生成并延缓Ma-1/HGF肿瘤的生长。Golvatinib与ZD1839联合使用可显著抑制肿瘤生长。[3]

激酶实验
Western blot analysis: The phosphorylation status of c-Met and VEGFR-2 is detected by Western blot analysis. For c-Met, MKN45 cells are incubated with a serial dilution of E7050 in complete medium at 37 °C for 2 h. For VEGFR-2, HUVEC are starved with human endothelial serum free medium containing 0.5% FBS for 24 h. Subsequently HUVEC are incubated with a serial dilution of E7050 for 1 h and then incubated with 20 ng/mL of human VEGF for 5 min. Cells are lysed by lysis buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EDTA [pH 8.0], 100 mM NaF, 1 mM phenylmethylsulfonyl fluoride 1 mM sodium orthovanadate, 10 μg/mL aprotinin, 50 μg/mL leupeptin, and 1 μg/mL pepstatin A). The resected tumor samples are homogenized with lysis buffer containing 25 mM β-glycerophosphate and 0.5% (v/v) phosphatase inhibitor cocktail 2 at 4 °C. Cellular debris is removed by centrifugation at 17 860 g for 20 min at 4 °C. Aliquots of the supernatants containing 5-20 μg of protein are subjected to SDS-PAGE under reducing conditions. The proteins are then transferred onto PVDF membranes, blocked with TBS containing 0.05% Tween-20 and either 5% skim milk or 5% BSA. The membranes are probed with the following antibodies: anti-c-Met polyclonal antibody (C-28) and anti-VEGFR-2 polyclonal antibody (C-20); mouse anti-phosphotyrosine clone 4 g10; and anti-VEGFR-2 polyclonal antibody, anti-phospho-VEGFR-2 (Tyr996) polyclonal antibody, and anti-phospho-c-Met (Tyr1234/1235) polyclonal antibody. Detection is performed using a Super Signal enhanced chemiluminescence kit. Immunoreactive bands are visualized by chemiluminescence with an Image Master-VDS-CL detection system. The intensity of each band is measured by using an image analyzer.
细胞实验
Cells (1–3 × 103 cells/100 μL/well) are seeded on 96-well culture plates with various concentrations of E7050 and cultured for 3 days. Then, 10 μL of WST-8 reagent is added to each well, and absorbance is measured at 450 nm compared with a reference measurement at 660 nm using a MTP-500 microplate reader. HUVEC (2 × 103 cells/well) are cultured for 3 days in medium containing HGF (30 ng/mL), VEGF (20 ng/mL), or basic fibroblast growth factor (bFGF) (20 ng/mL) together with serially diluted E7050.(Only for Reference)
别名
戈伐替尼, E-7050
化学信息
分子量633.69
分子式C33H37F2N7O4
CAS No.928037-13-2
SmilesCN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1
密度1.408 g/cm3
储存&溶解度
存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

实际储存温度请以COA为准

溶解度信息
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 100 mg/mL (157.81 mM)
体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (6.31 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM1.5781 mL7.8903 mL15.7806 mL78.9029 mL
5 mM0.3156 mL1.5781 mL3.1561 mL15.7806 mL
10 mM0.1578 mL0.7890 mL1.5781 mL7.8903 mL
20 mM0.0789 mL0.3945 mL0.7890 mL3.9451 mL
50 mM0.0316 mL0.1578 mL0.3156 mL1.5781 mL
100 mM0.0158 mL0.0789 mL0.1578 mL0.7890 mL
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSOPEG300PEG400Tween 80SBE-β-CD玉米油等, 均可在TargetMol网站点击购买。
1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

Related Tags: buy Golvatinib | purchase Golvatinib | Golvatinib cost | order Golvatinib | Golvatinib chemical structure | Golvatinib in vivo | Golvatinib in vitro | Golvatinib formula | Golvatinib molecular weight